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Introduction
Acute renal failure (ARF) is a common complication of
Rhabdomyolysis (RBM), a syndrome characterized by
muscle breakdown and necrosis resulting in the leakage
of the intracellular constituents into the circulation and
the extracellular fluid. It is estimated that about 10-50%
of patients with RBM develop ARF.
Objectives
All the classic treatments for RBM have demonstrated
only partial efficacy. Intravascular volume expansion, urin-
ary alkalinization, and forced diuresis are currently used as
renal-protective measures but are not useful in the context
of severe oliguria. Acute kidney failure is treated by classi-
cal renal replacement therapies; it’s important to produce
also a significant removal of circulating myoglobin and the
use of blood purification techniques may be advantageous.
Literature has shown that previous attempts to remove
myoglobin using plasma exchange, intermittent hemodia-
lysis, and continuous renal replacement therapies (CRRT)
have unfortunately met with limited success. With an ana-
lysis of the literature, we aimed to evaluate a new solution
for the removal of myoglobin in the treatment of RBM,
represented by a dedicated sorbent that can be used both
in hemoperfusion (HP) and in combination with tradi-
tional CRRT.
Methods
Literature provided a published case study in which a
new adsorber, CytoSorbTM (CytoSorbents Corp) was
used in HP for 12h to remove myoglobin from blood in
a complex situation of legionella-pneumonia associated
RBM. CytoSorbTM is a sorbent made of an advanced
biocompatible porous polymer with high binding capa-
city and designed to reduce toxic levels of pro- and
anti-inflammatory mediators, myoglobin and bilirubin
directly from blood. The evidence found in literature is
supported by our clinical experience, not published yet,
regarding a patient with severe RBM and ARF, after
laparoscopic sleeve gastrectomy. The cartridge was used
for 24h and it was installed in a series connection after
the dialyzer into the CRRT circuit.
Results
The course of standard laboratory makers and myoglo-
bin levels are shown in the table. Results demonstrated
an important decrease of myoglobin levels and an
improvement in renal function both in stand-alone
mode and in combination with CRRT.
Conclusions
The use of new sorbents in continuous veno-venous filtra-
tion and HP might represent a novel approach to the
treatment of acute RBM not only because efficient renal
replacement may be provide but also because a potential
protective effect can be envisaged in the rapid and efficient
removal of circulating myoglobin and creatine kinase.
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Table 1 Results before and after the treatment.
HP CRRT + HP
T0 T1 Reduction T0 T1 Reduction
Creatinine
(mg/dL)
1,56 1,15 26,3% 3,4 2,1 38,2%
Myoglobin
(ng/mL)
18390 8359 54,6% 52998 8862 83,3%
Creatine Kinase
(U/L)
- - - 18587 8755 52,9%
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